AGIOS PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Agios Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2012 to Q3 2024.
  • Agios Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $948M.
  • Agios Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $674M.
  • Agios Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$352M, a 51.9% decline from 2022.
  • Agios Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$232M, a 114% decline from 2021.
  • Agios Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $1.6B.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $674M $948M +$1.04B Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$365M -$96.1M -$12.3M -14.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-31
Q1 2024 -$353M -$81.5M -$531K -0.66% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-31
Q4 2023 -$352M -$95.9M -$132M -363% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$220M -$91.3M -$9.58M -11.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$210M -$83.8M +$8M +8.71% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-31
Q1 2023 -$218M -$81M +$13.8M +14.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-31
Q4 2022 -$232M $36.5M +$131M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$363M -$81.7M +$7.02M +7.91% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$370M -$91.8M -$5.59M -6.48% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$364M -$94.8M -$1.97B -105% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 $1.6B -$94.6M +$3.03M +3.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $1.6B -$88.8M +$10.2M +10.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $1.59B -$86.2M +$4.26M +4.71% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 $1.59B $1.87B +$1.91B Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$327M -$97.7M +$4.69M +4.59% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$332M -$99M +$7.19M +6.78% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$339M -$90.5M +$19.4M +17.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-03
Q1 2020 -$359M -$40.3M +$52.8M +56.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-03
Q4 2019 -$411M -$102M -$10.6M -11.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$401M -$106M -$11.5M -12.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$389M -$110M -$41.1M -59.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$348M -$93.1M -$2.25M -2.48% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$346M -$91.8M -$3.51M -3.98% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$343M -$94.7M -$17.5M -22.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 -$325M -$68.7M +$14.3M +17.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-10-31
Q1 2018 -$339M -$90.8M -$24.7M -37.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-10-31
Q4 2017 -$315M -$88.3M -$65.1M -281% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-19
Q3 2017 -$250M -$77.1M -$14.3M -22.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$235M -$83.1M -$27.1M -48.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$208M -$66.2M -$43M -185% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 -$165M -$23.2M +$17.4M +42.9% Oct 1, 2016 Dec 31, 2016 10-Q 2017-05-04
Q3 2016 -$183M -$62.8M -$22.6M -56.1% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-01
Q2 2016 -$160M -$56M -$24.1M -75.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 -$136M -$23.2M -$18.2M -368% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 -$118M -$40.6M -$14M -52.3% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-14
Q3 2015 -$104M -$40.3M -$44M -1187% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 -$59.8M -$31.9M -$13.6M -74.3% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$46.2M -$4.96M +$7.29M +59.5% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 -$53.5M -$26.7M -$14.3M -115% Oct 1, 2014 Dec 31, 2014 10-K 2015-02-24
Q3 2014 -$39.2M $3.7M +$14.9M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 -$54.1M -$18.3M -$9.68M -112% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 -$44.4M -$12.2M -$5.02M -69.5% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q4 2013 -$39.4M -$12.4M -$7.07M -133% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-24
Q3 2013 -$32.3M -$11.2M -$6.53M -141% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-24
Q2 2013 -$25.8M -$8.62M -$3.11M -56.4% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-24
Q1 2013 -$22.7M -$7.23M -$2.6M -56.1% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-24
Q4 2012 -$20.1M -$5.31M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-18
Q3 2012 -$4.65M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-18
Q2 2012 -$5.51M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-18
Q1 2012 -$4.63M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.